Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

By Venturini M.   Bighin C.   Monfardini S.   Cappuzzo F.   Olmeo N.   Durando A.   Puglisi F.   Nicoletto O.   Lambiase A.   Mastro L.  

Breast Cancer Research and Treatment, Vol. 95, Iss. 1, 2006-01 ,pp. : 45-53

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

By Morales Serafín   Lorenzo Antonio   Ramos Manuel   Ballesteros Pedro   Méndez Miguel   Almanza Concepción   Castellanos Javier   Moreno-Nogueira José   Casal Joaquín   Lizón José   Oltra Amparo   Frau Adolfo   Machengs Ignacio   Galán Antonio   Belón Joaquín   Llorca Cristina  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 1, 2004-01 ,pp. : 75-81

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

By Yardley Denise A.   McCleod Michael   Schreiber Fred   Murphy Patrick   Patton Jeffrey   Thompson Dana S.   Shastry Mythili   Rubin Mark   Melnik Marianne   Burris Howard A.   Hainsworth John D.  

Cancer Investigation, Vol. 28, Iss. 9, 2010-10 ,pp. : 925-931

Informa Healthcare

Access to resources Recommend Favorite

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial

By Hatschek T.   Carlsson L.   Einbeigi Z.   Lidbrink E.   Linderholm B.   Lindh B.   Loman N.   Malmberg M.   Rotstein S.   Söderberg M.   Sundquist M.   Walz T.   Hellström M.   Svensson H.   Åström G.   Brandberg Y.   Carstensen J.   Fernö M.   Bergh J.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 939-947

Springer Publishing Company

Access to resources Recommend Favorite

Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: A retrospective cohort analysis

By Nelli Fabrizio   Natoli Guido   Moscetti Luca   Massari Annalisa   D’Auria Giuliana   Fabbri Maria A   Frittelli Patrizia   Ruggeri Enzo M  

Journal of Chemotherapy, Vol. 25, Iss. 2, 2013-04 ,pp. : 112-118

Maney Publishing

Access to resources Recommend Favorite